Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital

Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur

Research output: Contribution to journalJournal articleResearchpeer-review

  1. The prognostic effect of smoking status on intensively treated acute myeloid leukaemia - A Danish nationwide cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Smoking, blood cells and myeloproliferative neoplasms: meta-analysis and Mendelian randomization of 2·3 million people

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Methodological aspects of health-related quality of life measurement and analysis in patients with multiple myeloma

    Research output: Contribution to journalReviewResearchpeer-review

  4. Outcome of an enhanced diagnostic pipeline for patients suspected of inherited thrombocytopenia

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations
Mantle cell lymphoma (MCL) is a heterogenic non-Hodgkin lymphoma entity, with a median survival of about 5 years. In 2008 we reported the early - based on the median observation time of 4 years - results of the Nordic Lymphoma Group MCL2 study of frontline intensive induction immunochemotherapy and autologous stem cell transplantation (ASCT), with more than 60% event-free survival at 5 years, and no subsequent relapses reported. Here we present an update after a median observation time of 6·5 years. The overall results are still excellent, with median overall survival and response duration longer than 10 years, and a median event-free survival of 7·4 years. However, six patients have now progressed later than 5 years after end of treatment. The international MCL Prognostic Index (MIPI) and Ki-67-expression were the only independent prognostic factors. Subdivided by the MIPI-Biological Index (MIPI + Ki-67, MIPI-B), more than 70% of patients with low-intermediate MIPI-B were alive at 10 years, but only 23% of the patients with high MIPI-B. These results, although highly encouraging regarding the majority of the patients, underline the need of a risk-adapted treatment strategy for MCL. The study was registered at as ISRCTN 87866680.
Original languageEnglish
JournalBritish Journal of Haematology
Issue number3
Pages (from-to)355-62
Number of pages8
Publication statusPublished - 2012

    Research areas

  • Aged, Antibodies, Monoclonal, Murine-Derived, Antineoplastic Combined Chemotherapy Protocols, Carmustine, Cyclophosphamide, Cytarabine, Disease-Free Survival, Etoposide, Female, Hematopoietic Stem Cell Transplantation, Humans, Immunotherapy, Lymphoma, Mantle-Cell, Male, Melphalan, Middle Aged, Podophyllotoxin, Prognosis, Recurrence, Survival Rate, Transplantation, Autologous

ID: 36545302